Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice
about
Novel bile acid therapeutics for the treatment of chronic liver diseasesBile acids, obesity, and the metabolic syndromeThe bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in miceBile acid signaling in metabolic disease and drug therapyFarnesoid X receptor: from medicinal chemistry to clinical applicationsTrimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulationThe farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria.Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia.New developments in selective cholesteryl ester uptake.Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease.Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis.Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding.Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.Effect of chenodeoxycholic acid on fibrosis, inflammation and oxidative stress in kidney in high-fructose-fed Wistar rats.Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasisNuclear receptors in renal diseaseAPOE and FABP2 Polymorphisms and History of Myocardial Infarction, Stroke, Diabetes, and Gallbladder Disease.Bile Acid signaling in liver metabolism and diseases.Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice.The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin.Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease.The role of nuclear receptors in the kidney in obesity and metabolic syndromeTranscriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR.Association of potential salivary biomarkers with diabetic retinopathy and its severity in type-2 diabetes mellitus: a proteomic analysis by mass spectrometryFarnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic miceFXR an emerging therapeutic target for the treatment of atherosclerosisFarnesoid X Receptor and Its Ligands Inhibit the Function of Platelets.Farnesoid X receptor-Acting through bile acids to treat metabolic disorders.Bile acid receptors in non-alcoholic fatty liver disease.Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target.Sex differences in lipid metabolism and metabolic disease risk.Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.Molecular biology of atherosclerosis.Bile acid receptors as targets for drug development.The bile acid TGR5 membrane receptor: from basic research to clinical application.Roles of oxidative stress, adiponectin, and nuclear hormone receptors in obesity-associated insulin resistance and cardiovascular risk.Shp deletion prevents hepatic steatosis and when combined with Fxr loss protects against type 2 diabetes.MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor.Mechanisms of Action of Surgical Interventions on Weight-Related Diseases: the Potential Role of Bile Acids.Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice
P2860
Q26748613-C27B0A8A-56CB-497F-8516-49829CD8A18FQ27020976-F8CA533A-F1CD-4999-8017-E22811D65A85Q27318414-C357827C-067D-4983-A378-CCF2B20600FFQ28244875-E3FC4C68-D637-4A0F-BCDA-4BE9B4FD2094Q28266284-12C85CD3-FFFB-444E-BCEA-5E1EB82F9CA4Q28283087-1F8DEA80-0F1C-4716-9508-5B3F17B8061CQ33570124-FC1DE181-8DAC-4FAD-A8D2-6B6F49A4CB32Q33661459-48D3D19E-9C13-4CAE-BD37-CFB2E93C01A8Q33894679-C5AAEFD4-99A1-471A-820A-819E3E303BF0Q34019132-1C5455B3-DDF2-4003-B18A-280DF21266BFQ34215923-80DEF8E8-A94F-499A-8DDC-31DDA894EE23Q34249416-4AB62216-D490-4985-8C9D-084D1DD9363AQ34310071-9BB49C9C-B6E5-46AC-8AF0-AD73AAFB656AQ34403105-A4222D82-4720-41FC-841A-60C3D0D86EF8Q35107308-7C3FFAA0-8D38-481E-9DE5-9FFBDB08AF1CQ35120702-51B2CFA7-EB74-4ABB-8F42-870E68AD5830Q35220171-A6A94DD8-844D-4B93-963F-FE11C0B2C55BQ35257218-014482CB-918C-4FB3-BDDE-F02B94A0CC80Q35744019-F312F9FD-667F-4030-940F-7472D320994BQ36020304-5A82E3FA-068D-4A54-BF11-65481717629AQ36145170-35792119-A6E1-457D-991A-7FE6FAE199EAQ36250127-4E4493B1-5EA8-4578-9CB5-73346F96028BQ36683297-DC13E1CC-63F4-499D-89B3-AB60345D519CQ36969424-950B10BC-9346-47EB-834B-9F97BFA07714Q37002680-B0A086FA-9CA6-4E2B-BB37-092162CA0036Q37334984-E5DF8C18-0E3B-4808-9151-8E4DE19D6C77Q37485728-B82BE51B-E0ED-45D9-906C-F7C34EA05058Q37508029-E7CE8CEA-C0C2-4AA5-A4C5-D225D72FF1CAQ37586952-E68C7CC0-B3B8-4546-8C6B-929CC9787941Q37970350-D73A16E1-50E4-4568-9F9A-2ED078E68912Q37973437-3F5AA5F8-5988-4CEC-8457-318F325CED93Q38014901-91616FA8-0DA6-4A64-8479-BDE421AB68A2Q38125279-E814822C-742A-406A-BB52-56E83991513DQ38132058-E4FEEC96-E522-43F5-AAA4-FF4453BCB17BQ38177434-D902AA53-A815-4A29-9B6D-F3081E29027FQ38267491-AF93ABE8-3954-40AB-8F96-2513EBEC8B8FQ38740970-E7AB67BB-6C87-48DD-B52E-E487753B5903Q38898464-E70A91F8-6705-48D7-A8B9-6BCB211BF23BQ39090294-FF06A541-4D13-448C-B3DE-3274DB0F6A0AQ41643121-FEC0156E-8ED9-46F6-9169-579449419008
P2860
Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Activation of farnesoid X rece ...... on in LDLR-/- and apoE-/- mice
@en
Activation of farnesoid X rece ...... n in LDLR-/- and apoE-/- mice.
@nl
type
label
Activation of farnesoid X rece ...... on in LDLR-/- and apoE-/- mice
@en
Activation of farnesoid X rece ...... n in LDLR-/- and apoE-/- mice.
@nl
prefLabel
Activation of farnesoid X rece ...... on in LDLR-/- and apoE-/- mice
@en
Activation of farnesoid X rece ...... n in LDLR-/- and apoE-/- mice.
@nl
P2093
P2860
P1476
Activation of farnesoid X rece ...... on in LDLR-/- and apoE-/- mice
@en
P2093
Chris J Petucci
Helen B Hartman
Julie A Krueger
Mark J Evans
Shuguang Wang
Stephen J Gardell
P2860
P304
P356
10.1194/JLR.M800619-JLR200
P577
2009-01-27T00:00:00Z